{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:08:24Z","timestamp":1790705304605,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"DOI":"10.1097\/qad.0b013e32835f2b49","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T12:06:39Z","timestamp":1360670799000},"page":"1413-1419","source":"Crossref","is-referenced-by-count":65,"title":["Differential penetration of raltegravir throughout gastrointestinal tissue"],"prefix":"10.1097","volume":"27","author":[{"given":"Kristine B.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Madanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D.M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of AIDS treatment in the United States.","volume":"194","author":"Walensky","year":"2006","journal-title":"J Infect Dis"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"The Antiretroviral Therapy Cohort CollaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.","volume":"372","author":"Hogg","year":"2008","journal-title":"Lancet"},{"key":"R4-7-20210130","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4() T cells during primary HIV-1 infection.","volume":"95","author":"Chun","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2007.03437.x","article-title":"Acute HIV infection: the impact of antiretroviral treatment on cellular immune responses.","volume":"149","author":"Hicks","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"R8-7-20210130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1084\/jem.20040874","article-title":"CD4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.","volume":"200","author":"Brenchley","year":"2004","journal-title":"J Exp Med"},{"key":"R9-7-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection.","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/nm1295-1284","article-title":"In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.","volume":"1","author":"Chun","year":"1995","journal-title":"Nat Med"},{"key":"R11-7-20210130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat Med"},{"key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"16725","DOI":"10.1073\/pnas.0804192105","article-title":"HIV rebounds from latently infected cells, rather than from continuing low-level replication.","volume":"105","author":"Joos","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-7-20210130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1086\/314678","article-title":"A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.","volume":"179","author":"Davey","year":"1999","journal-title":"J Infect Dis"},{"key":"R15-7-20210130","doi-asserted-by":"crossref","first-page":"12955","DOI":"10.1073\/pnas.2233345100","article-title":"Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.","volume":"100","author":"Brooks","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-7-20210130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrmicro1580","article-title":"Experimental approaches to the study of HIV-1 latency.","volume":"5","author":"Han","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"R17-7-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0009390","article-title":"Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4 cell infection.","volume":"5","author":"Archin","year":"2010","journal-title":"PLoS One"},{"key":"R18-7-20210130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","article-title":"Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4 T cells.","volume":"22","author":"Archin","year":"2008","journal-title":"AIDS"},{"key":"R19-7-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"R20-7-20210130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet"},{"key":"R21-7-20210130","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/JVI.02033-10","article-title":"Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4 T cell model without inducing global T cell activation.","volume":"85","author":"Xing","year":"2011","journal-title":"J Virology"},{"key":"R22-7-20210130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMe0804289","article-title":"HIV integrase inhibitors: out of the pipeline and into the clinic.","volume":"359","author":"Havlir","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-7-20210130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/infdis\/jir059","article-title":"Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.","volume":"203","author":"Brown","year":"2011","journal-title":"J Infect Dis"},{"key":"R24-7-20210130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0b013e31825cb645","article-title":"Single and multiple dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.","volume":"61","author":"Brown","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-7-20210130","first-page":"1524","article-title":"A new rectal model for dosimetry applications.","volume":"40","author":"Mardirossian","year":"1999","journal-title":"J Nucl Med"},{"key":"R28-7-20210130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/clpt.2010.189","article-title":"Pharmacologic opportunities for HIV prevention.","volume":"88","author":"Nicol","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R29-7-20210130","doi-asserted-by":"crossref","first-page":"112re4","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci Transl Med"},{"key":"R31-7-20210130","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.334.6063.1614","article-title":"HIVAIDS research. Tissue says blood is misleading, confusing HIV cure efforts.","volume":"334","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"R32-7-20210130","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/QAI.0b013e3181ae69c5","article-title":"Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.","volume":"51","author":"Dumond","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R33-7-20210130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jpba.2012.05.035","article-title":"A novel ultrasensitive LC-MSMS assay for quantification of intracellular raltegravir in human cell extracts.","volume":"70","author":"Robbins","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"R34-7-20210130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jchromb.2006.05.043","article-title":"Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.","volume":"843","author":"King","year":"2006","journal-title":"J Chromat B"},{"key":"R35-7-20210130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill.","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"R36-7-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R37-7-20210130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-7-20210130","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","article-title":"Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.","volume":"21","author":"Murray","year":"2007","journal-title":"AIDS"},{"key":"R39-7-20210130","doi-asserted-by":"crossref","first-page":"e1000321","DOI":"10.1371\/journal.pmed.1000321","article-title":"The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.","volume":"7","author":"Gandhi","year":"2010","journal-title":"PLoS Med"},{"key":"R40-7-20210130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4 T cell response.","volume":"203","author":"Hatano","year":"2011","journal-title":"J Infect Dis"},{"key":"R41-7-20210130","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-7-20210130","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R43-7-20210130","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/656722","article-title":"Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.","volume":"202","author":"Yukl","year":"2010","journal-title":"J Infect Dis"},{"key":"R44-7-20210130","doi-asserted-by":"crossref","first-page":"e33948","DOI":"10.1371\/journal.pone.0033948","article-title":"Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.","volume":"7","author":"Ananworanich","year":"2012","journal-title":"PLoS One"},{"key":"R45-7-20210130","doi-asserted-by":"crossref","first-page":"e1002774","DOI":"10.1371\/journal.ppat.1002774","article-title":"A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.","volume":"8","author":"Shytaj","year":"2012","journal-title":"PLoS Pathog"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32835f2b49","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:35:03Z","timestamp":1620970503000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201306010-00007"}},"subtitle":["implications for eradication and cure"],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32835f2b49","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}